About this episodeThe guest, CEO of Diversified Botanics, details the rapid growth of the kratom industry and the emergence of h…AI summary
The guest, CEO of Diversified Botanics, details the rapid growth of the kratom industry and the emergence of highly potent synthetic derivatives like 7-hydroxy mitragynine (70) and pseudoindoxynol, which pose significant addiction risks. He advocates for a harm-reduction regulatory framework that separates natural kratom from concentrated extracts, utilizing blockchain for supply chain transparency and AI for safety validation to counter cartel and foreign government interference.
Key takeaways 5
7-hydroxy mitragynine (70) is a metabolite of mitragynine that is 13-30 times more potent than morphine and lacks a 'ceiling effect,' leading to rapid addiction and severe withdrawal symptoms, unlike natural full-spectrum kratom which contains antagonists that buffer opioid receptor binding.
The supplement industry operates in a regulatory vacuum where products can be sold without FDA pre-market safety approval, allowing unscrupulous actors to introduce dangerous substances like contaminated or highly concentrated extracts into gas stations and smoke shops.
The guest's company faced threats from the Sinaloa cartel and evidence of Chinese Communist Party (CCP) involvement in destabilizing the US market by shipping solvents to US manufacturers to create addictive derivatives, prompting the need for advanced security and intelligence gathering.
Blockchain technology can solve supply chain transparency by creating immutable, multi-party validated records (nodes held by FDA, banks, suppliers) that prevent fraud and verify the origin and testing of raw materials, countering AI-generated misinformation.
A proposed regulatory model suggests natural kratom should be sold in mainstream retail (21+), while concentrated extracts should be restricted to dispensary or pharmacy settings with strict dosage caps and mandatory harm-reduction support for users.
Notable quotes 4AI-generated: wording and quote attribution may be wrong. Use the play link to verify.
“70 operates 13 to 30 times more potently than morphine... When you consume a capsule of product... each one of those tabs was 10 milligrams... now when you pull up some of the more recent tabs... you're going to see a pack of four tabs is 200 mg of 7 hydroxy.”
▶ 54:52Explaining the extreme potency and escalating dosages of synthetic kratom derivatives compared to natural plant material.
“When you swallow the seeds [of an apple], nothing happens... However, if somebody else took all the seeds out... soaked them... those seeds turn into something very different. Those seeds turn into cyanide... That is the difference in full spectrum versus 7 hydroxy.”
Using an analogy to explain why natural kratom (with buffering alkaloids) is safer than isolated 70 (the 'seed' or concentrated toxin).
“We've got kids as young as 15 being [addicted]... we've got video and evidence... I show it to a senator congressman and said like this is your state... and nothing.”
▶ 2:27:52Highlighting the failure of political leadership to address the public health crisis caused by unregulated kratom extracts.
“If you don't believe what is it that... If you don't stand for something, you fall for everything... I at least stand for this right now.”
▶ 2:33:56The guest's personal motivation for risking his safety to lobby against dangerous derivatives despite threats from cartels.
Chapters & Sections (124)▼
0:00Cartel Involvement in Pharmaceutical Industrychapter2
0:00Cartel Involvement in Pharmaceutical Industry
2:55CEO Discusses Company and Modern Legalization
5:29Introduction to the Kratom Plantchapter3
5:29Introduction to the Cat Ratom Plant
7:01Ratam's Dual Effects and Preparation Methods
8:41History of Kratom Consumption in the US
10:00History of Supplement Industry and Product Developmentchapter2
10:00History of Supplement Industry and Product Development
12:42Regulatory Loopholes in the Supplement Industry
14:34Supplement Industry Quality Control and Regulationchapter3
14:34Supplement Industry Lack of Quality Control
16:48Risks and Regulation of Synthetic Cannabinoids
18:45Regulatory Scheduling of Highly Potent Opioids
19:59Salmonella Outbreak and Kratom Contaminationchapter2
19:59Salmonella Outbreak Linked to Kratom Consumption
22:29Regulatory Challenges in Psychedelic Plant-Based Business
24:33The Discovery of a Potent New Substancechapter4
24:33Founding Story of a Supplement Company
26:08Risks of Unregulated Substance Legalization
27:22Regulatory Challenges in Conducting Safety Studies
28:40Conducting FDA-Approved Clinical Trials for New Drugs
30:13Challenges of Validating New Pharmaceutical Substanceschapter4
30:13Challenges of Validating New Pharmaceutical Substances
32:06Regulation of Dietary Supplements in Industry
33:14Combining AI, Quantum, and Blockchain in Supplement Industry
34:34Unlocking Hidden Connections in Scientific Research
36:07Lack of Regulation in Food and Product Labelingchapter3
36:07Monopolies and Lack of Product Regulation
38:10Deception in Organic and Grass-Fed Labeling Practices
39:37Marketing Influence on Consumer Choices
40:50The Risks of Forever Chemicals in Everyday Productschapter4
40:50The Risks of Non-Degradable Chemicals in Everyday Life
42:24Consequences of Unintended Consequences in Society
43:57Cycles of History and Industry Evolution
45:28Opioid Replacement Industry Misrepresentation
46:39Opioid Receptors and Agonist Mechanisms Explainedchapter2
46:39Opioid Receptors and Agonist Mechanisms Explained
48:32Confusion Around Potent Opioid Metabolites Explained
50:58Metagenine's Chemical Composition and Testing Protocolschapter3
50:58Metragene's Potency and Safety Testing Protocols
52:52Searching for Manufacturing Capacity for Psychedelic Research
54:11Isolation and Potency of 7 Hydroxy Metroine
56:00Opioid Analgesic Effects and Addiction Potentialchapter3
56:00Opioid Analgesic Effects and Addiction Potential
58:43Comparing Potency of 7 Hydroxy to Morphine
59:54Bioavailability of Medicinal Products in the Body
1:01:27Phytochemical Interactions and Potency in Plantschapter2
1:01:27Phytochemical Interactions in Full Spectrum Substances
1:03:23Risks of 7 Hydroxy Cannabinoid Overdose
1:05:36Rat Park Experiment and Opioid Addictionchapter2
1:05:36Risks of High-Dose Synthetic Opioid Use
1:07:03Addiction to Highly Potent Synthetic Opioid
1:09:52Mainstreaming a Potent, Legally Classified Drugchapter3
1:09:52Breaking into Mainstream Cannabis Industry
1:11:28Rethinking the Approach to Pharmaceutical Development
1:12:46Navigating the Challenges of High-Potency Medications
1:14:02Addiction and Regulation of Potent Opioid Alternativeschapter3
1:14:02Addiction and Regulation of Potent Opioid Alternatives
1:15:53FDA Regulation of Emerging Psychedelic Substances
1:17:05Transparency in Pharmaceutical Manufacturing Process
1:18:29Responding to Wrongful Death Lawsuit Allegationschapter2
1:18:29Responding to Wrongful Death Lawsuit Allegations
1:20:15Ratam Toxicity and Heart Attack Investigation
1:22:51Bioavailability of Supplements Interacting with Other Substanceschapter10
1:22:51Unexpected Interactions with Bioavailability and Supplements
1:24:42Contraindications and Product Safety Measures
1:27:02Supply Chain Transparency and Product Safety Measures
1:28:48Blockchain Technology in Food Supply Chain
1:30:06Blockchain Validation and Data Transparency
1:31:46Blockchain Validation in Supply Chain Management
1:33:13Blockchain Anonymity and Time Stamping Validation
1:34:35Blockchain-Based Anti-Illicit Fishing System
1:36:29Blockchain Validation in the Age of AI
1:38:16Blockchain Security and Transparency in Business
1:40:24Rapid Advancements in AI Technology and Its Implicationschapter3
1:40:24Rapid Advancements in AI Technology and Implications
1:41:42Simulation Theory and Existential Questions
1:44:24Philosophical Implications of Simulation Hypothesis
1:46:10Regulating Highly Potent Opioids in the Marketchapter2
1:46:10Regulating Highly Potent Opioids in the Market
1:48:36Addictive Properties of Potent Opioids
1:50:45Opioid Crisis and the Rise of New Substanceschapter2
1:50:45Opioid Crisis and New Synthetic Opioid Market
3h 3m⏭ 2
2h 49m⏭ 3
2h 58m⏭ 2
3h 18m⏭ 1
2h 50m⏭ 2
3h 18m⏭ 2
3h 3m⏭ 2
3h 3m⏭ 2
3h 11m⏭ 1
2h 31m⏭ 5
2h 44m⏭ 4
2h 54m⏭ 1
2h 27m⏭ 6
2h 6m⏭ 2
1h 27m
1h 56m⏭ 2
2h 9m⏭ 8
1h 37m⏭ 3
1h 45m
1h 46m⏭ 3
1h 40m⏭ 3
4h 22m
1h 28m
2h 24m⏭ 8
1h 0m⏭ 1
33m
46m
3h 59m⏭ 5
3h 54m⏭ 7
54m⏭ 1
1h 13m
54m⏭ 2
1h 26m
45m⏭ 2
58m⏭ 5
25m